ClinicalTrials.gg
CompletedNCT02195466Updated Jul 21, 2014

Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers

A Phase 1 interventional study of Tipranavir (TPV) and Ritonavir (RTV) in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-21.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Study to determine the effects of single-dose and steady-state TPV/RTV 500/200 mg on the steady-state pharmacokinetics of fluconazole

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between 18 and 60 years of age inclusive
  • A (BMI) between 18 and 29 kg/m2
  • Signed prior to trial participation
  • Ability to swallow multiple large capsules without difficulty
  • Acceptable laboratory values that indicate adequate baseline organ function are required at the time of screening. Laboratory values are considered to be acceptable if severity is less than or equal to Grade 1, based on the AIDS Clinical Trials Group (ACTG) Grading Scale. All abnormal laboratory values greater than Grade 1 are subject to approval by the trial clinical monitor
  • Acceptable medical history, physical examination, 12-lead , and chest X-ray (if not conducted within the last 12 months and deemed necessary by investigator) are required prior to entering the treatment phase of the study
  • Willingness to abstain from the following starting 14 days prior to any administration of study drugs up until the end of the study:

    • Grapefruit or grapefruit juice
    • Red wine
    • Seville oranges
    • St. John's Wort or Milk Thistle
  • Willingness to abstain from alcohol starting 2 days prior to administration study drug up to the end of the study
  • Willingness to abstain from the following within 72 hours of pharmacokinetics (PK) sampling:

    • Garlic supplements
    • Methylxanthine containing drinks (coffee, tea, cola, energy drinks, chocolate, etc.)
  • Willingness to abstain from over the counter herbal medications for the duration of the study
  • Have been non-smokers for 3 months
  • Willingness to abstain from vigorous physical exercise during intensive PK Days 6, 7, 13
  • Reasonable probability for completion of the study

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are of and:

    • Have a positive serum β-human chorionic gonadotropin (hCG) at Visit 1, or on Day 0 or Day 1
    • Have not been using a barrier method for at least 3 months prior to Visit 3 (Day 1)
    • Are not willing to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during the trial and 60 days after completion/termination
    • Are breast-feeding
  • Participation in another trial with an medicine within 60 days prior to Day 0 (Visit 2)
  • Use of any prohibited medication listed in the protocol within 30 days prior to Day 0 (Visit 2)
  • Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month of study initiation and for the duration of the study. Use of Depo-Provera is excluded for six months prior to study initiation
  • Use of hormone replacement therapy within 1 month of study initiation and for the duration of the study
  • Administration of antibiotics within 10 days prior to Day 0 (Visit 2) or during the trial
  • History of acute illness within the past 60 days. Subjects will be excluded for these disorders greater than sixty days if, in the opinion of the investigator, the subject does not qualify as a healthy volunteer
  • History of thrombotic disease
  • History of migraine headache
  • Have serological evidence of virus (HBV) or virus (HCV)
  • Have serological evidence of exposure to
  • Recent history of alcohol or substance abuse (within 1 year of study period)
  • Blood or plasma donations within 30 days of Day 0 (Visit 2) or during the trial
  • Subjects with a seated systolic blood pressure either \<100 mm Hg or >150 mm Hg; resting heart rate either \<50 beats/min or >90 beats/min. For subjects with a resting heart rate below 50, or above 90, the investigator may discuss exclusion with the medical monitor on a case-by-case basis
  • Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering TPV, RTV or FCZ to the subject
  • Subjects who have had an acute illness within 2 weeks prior to Day 0 (Visit 2)
  • Subjects who are currently taking any over-the-counter or prescription drug within 7 days prior to Day 0 (Visit 2) that, in the opinion of the investigator in consultation with the Boehringer Ingelheim (Canada) Ltd./Ltée clinical monitor, might interfere with either the absorption, distribution or metabolism of the test substances
  • Known to TPV, RTV, FCZ, or sulphonamide class of drugs
  • Inability to adhere to the protocol
  • Cautions or warnings in the FCZ package insert which, in the judgment of the investigator, should exclude a subject from the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    TPV + RTV + FCZ

    Drug: Tipranavir (TPV) · Drug: Ritonavir (RTV) · Drug: Fluconazole (FCZ)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration time curve from 0-24 hours (AUC0-24h) for FCZ

    Time frame: up to 24 hours after administration of study drug

  2. Maximum plasma concentration (Cmax) for FCZ

    Time frame: up to 24 hours after administration of study drug

  3. Drug concentration in plasma at 24 hours after administration (Cp24h) for FCZ

    Time frame: up to 24 hours after administration of study drug

Secondary outcomes

  1. AUC0-12h for TPV

    Time frame: up to 12 hours after administration of study drug

  2. Cmax for TPV

    Time frame: up to 24 hours after administration of study drug

  3. Drug concentration in plasma at 12 hours after administration (Cp12h) for TPV

    Time frame: up to 12 hours after administration of study drug

  4. Oral clearance (Cl/F) for FCZ and TPV

    Time frame: up to 24 hours after administration of study drug

  5. Time of maximum concentration (tmax) for FCZ and TPV

    Time frame: up to 24 hours after administration of study drug

  6. Apparent terminal half life (t1/2) for FCZ and TPV

    Time frame: up to 24 hours after administration of study drug

  7. Number of patients with adverse events

    Time frame: up to 6 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a primary completion of Jul 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2014
First posted
Jul 21, 2014
Start
Jun 2003
Primary completionActual
Jul 2003
Last update
Jul 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02195466
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Jun 2003
Primary completion
Jul 2003
Last update
Jul 21, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir · Fluconazole

Start the discussion